Photodynamic therapy gains FDA approval for superficial BCC - Quiz - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Photodynamic therapy gains FDA approval for superficial BCC

Phase 3 trial data showed greater clinical and histological clearance than with placebo photodynamic therapy.

  • By

  • Kathryn Wighton

  • September 15, 2026

  • 2 min

Share

Original Source(s)

Photodynamic therapy gains FDA approval for superficial BCC

  • by Kathryn Wighton

  • September 15, 2026

Related Content

Sun Protection 101—Your Guide to Sunscreen

Prospective Evidence on Artificial Intelligence−Assisted Melanoma Diagnostics: A Systematic Review and

Teledermatology in Community Settings for Prompt Evaluation of Suspected Skin Cancer: A Cost-Effectiveness Analysis and Discrete Event Simulation Study